Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Immunovant ends cutaneous lupus program after phase 2 flop

Immunovant ends cutaneous lupus program after phase 2 flop

September 23, 2026Posted inBiotechnology

Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.

Post navigation

Previous Post
Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
Next Post
Enveda reaps $311M series E to feed ambition to become a ‘household name’

Recent Posts

  • Four-Year-Old Receives China’s Youngest Documented Leadless Pacemaker Implantation
  • Questionnaire Layout Associated With Response Patterns in Orthopaedic Patient Surveys
  • Lower Vitamin D and Magnesium Levels Track Degenerative Temporomandibular Disorders
  • Immune Microenvironment Breakdown at Neuromuscular Junctions Drives Early Sarcopenia
  • LoRA-BERT Accurately Predicts Long Non-Coding RNAs Even From Partial Transcripts

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top